Secukinumab In Patients With Moderate to Severe Active, Chronic Plaque Psoriasis Who Have Failed on TNFα antaGoNists: A Clinical Trial EvalUating Treatment REsults
Phase of Trial: Phase III
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms SIGNATURE
- Sponsors Novartis Pharmaceuticals
- 07 Jun 2017 Biomarkers information updated
- 21 Sep 2016 Status changed from active, no longer recruiting to completed.
- 02 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Aug 2016.